Details

Autor(en) / Beteiligte

• Xu, Jian

Titel

Bi-anti therapy for SARS-CoV-2 infection among mild/moderate patients to prevent coronavirus disease 2019 from progressing to severe disease

Ist Teil von

• Journal of translational medicine, 2023-02, Vol.21 (1), p.87-87, Article 87

Ort / Verlag

England: BioMed Central Ltd

Erscheinungsjahr

2023

Link zum Volltext

Quelle

SpringerLink Journals - AutoHoldings

Beschreibungen/Notizen

• SARS-CoV-2 infection is an initial factor to cause host damage. [...]it is speculated that the damage of early patients is mainly related to the direct attack of the virus on the host, antiviral therapy early might be a useful strategy for preventing disease from progressing into severe or critical cases. Non-steroidal anti-inflammatory drugs (NSAIDs) and glucocorticoids seem to be a valuable therapeutic strategy for anti-inflammatory to reduce severe COVID-19-related illness in the outpatient stage of COVID-19. [...]as shown in Fig. 1, we recommend “bi-anti” (antiviral and anti-inflammatory simultaneously) therapy in an outpatient setting at the early stages of SARS‐CoV‐2 infection. SEE PDF] Overall, SARS-CoV-2 infection is only the initiating factor of the COVID-19, and the host’s immune response induced by SARS-CoV-2 is the key factor resulting in the disease progression. [...]we propose the concept of “bi-anti” at the mild/moderate stage of SARS-CoV-2 infection to prevent the COVID-19 from developing into severe or critical disease.